Free tool
Rare disease stocks
We cover 135 companies grouped under the Rare disease theme. The median market value in the group is $1.39B. Across the group, the median move over the past trading day is −0.63%. 70% of the 129 with a 200-day average trade above it. Price change over the past year runs from −37.7% to +275.9% across the middle 80 percent of the group, with a median of +53.1%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
135 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| VRTX34.SA | Vertex Pharmaceuticals Incorporated | $139.70B | Large cap | −83.18% |
| VRTX | Vertex Pharmaceuticals Incorporated | $138.63B | Large cap | +40.66% |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% |
| A1RG34.SA | argenx SE | $63.16B | Large cap | +36.97% |
| ALNY | Alnylam Pharmaceuticals, Inc. | $32.12B | Large cap | −47.38% |
| A1LN34.SA | Alnylam Pharmaceuticals, Inc. | $31.78B | Large cap | −49.35% |
| INSM | Insmed Incorporated | $27.16B | Large cap | −7.54% |
| ROIV | Roivant Sciences Ltd. | $26.55B | Large cap | +206.51% |
| JAZZ | Jazz Pharmaceuticals plc | $16.89B | Large cap | +100.35% |
| ASND | Ascendis Pharma A/S | $16.41B | Large cap | +29.66% |
| BBIO | BridgeBio Pharma, Inc. | $15.52B | Large cap | +60.05% |
| CORT | Corcept Therapeutics Incorporated | $12.95B | Large cap | +71.81% |
| BMRN | BioMarin Pharmaceutical Inc. | $12.70B | Large cap | +11.85% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | $12.54B | Large cap | +4.97% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.52B | Large cap | +308.99% |
| CYTK | Cytokinetics, Incorporated | $11.01B | Large cap | +109.36% |
| IONS | Ionis Pharmaceuticals, Inc. | $10.56B | Large cap | +48.21% |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +197.09% |
| PTGX | Protagonist Therapeutics, Inc. | $9.80B | Mid cap | +146.62% |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +9.35% |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | +555.07% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +154.86% |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +356.93% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.07B | Mid cap | +46.02% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +31.96% |
| GRFS | Grifols, S.A. | $5.38B | Mid cap | −19.39% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +207.13% |
| MANE | Veradermics, Incorporated | $4.29B | Mid cap | +172.32% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| CLDX | Celldex Therapeutics, Inc. | $3.19B | Mid cap | +79.51% |
| IRON | Disc Medicine, Inc. | $3.17B | Mid cap | +37.90% |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +60.64% |
| VRDN | Viridian Therapeutics, Inc. | $2.75B | Mid cap | +30.71% |
| VERA | Vera Therapeutics, Inc. | $2.65B | Mid cap | +67.21% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −12.10% |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% |
| TRVI | Trevi Therapeutics, Inc. | $2.55B | Mid cap | +124.00% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +151.95% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +15.38% |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.30B | Mid cap | +44.68% |
| MLYS | Mineralys Therapeutics, Inc. | $2.28B | Mid cap | +70.22% |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | Mid cap | +36.58% |
| ADMA | ADMA Biologics, Inc. | $2.16B | Mid cap | −44.17% |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | +97.73% |
| STOK | Stoke Therapeutics, Inc. | $2.14B | Mid cap | +71.45% |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $2.03B | Mid cap | −13.45% |
| SEPN | Septerna, Inc. | $1.88B | Small cap | +218.81% |
| ETON | Eton Pharmaceuticals, Inc. | $1.79B | Small cap | +262.38% |
| ANAB | AnaptysBio, Inc. | $1.73B | Small cap | +326.47% |
| ANIP | ANI Pharmaceuticals, Inc. | $1.71B | Small cap | −18.85% |
| MAZE | Maze Therapeutics, Inc. | $1.69B | Small cap | +113.27% |
| AVLN | Avalyn Pharma Inc. | $1.64B | Small cap | +25.60% |
| FBRX | Forte Biosciences, Inc. | $1.63B | Small cap | +589.87% |
| XERS | Xeris Biopharma Holdings, Inc. | $1.58B | Small cap | +8.64% |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.58B | Small cap | +132.58% |
| A2RR34.SA | Arrowhead Pharmaceuticals, Inc. | $1.58B | Small cap | +298.89% |
| TYRA | Tyra Biosciences, Inc. | $1.56B | Small cap | +103.57% |
| KALV | KalVista Pharmaceuticals Inc | $1.44B | Small cap | +98.68% |
| OMER | Omeros Corporation | $1.40B | Small cap | +328.71% |
| JBIO | Jade Biosciences, Inc. | $1.39B | Small cap | +168.30% |
| MLTX | MoonLake Immunotherapeutics | $1.32B | Small cap | −71.82% |
| SVRA | Savara Inc. | $1.15B | Small cap | +70.52% |
| AVTX | Avalo Therapeutics, Inc. | $1.10B | Small cap | +112.95% |
| WVE | Wave Life Sciences, Inc. | $1.03B | Small cap | −48.12% |
| DSGN | Design Therapeutics, Inc. | $975.65M | Small cap | +194.71% |
| ANNX | Annexon, Inc. | $946.00M | Small cap | +136.49% |
| DBVT | DBV Technologies S.A. | $940.80M | Small cap | +53.00% |
| CLYM | Climb Bio Inc | $923.57M | Small cap | +603.72% |
| PHAR | Pharming Group N.V. | $845.80M | Small cap | −14.47% |
| SLN | Silence Therapeutics plc | $840.94M | Small cap | +160.19% |
| STTK | Shattuck Labs, Inc. | $792.87M | Small cap | +690.00% |
| ASMB | Assembly Biosciences, Inc. | $721.17M | Small cap | +36.81% |
| IRWD | Ironwood Pharmaceuticals, Inc. | $708.88M | Small cap | +240.48% |
| GYRE | Gyre Therapeutics, Inc. | $705.12M | Small cap | −18.00% |
| AGMB | AgomAb Therapeutics NV | $703.26M | Small cap | −2.53% |
| TECX | Tectonic Therapeutic, Inc. | $703.19M | Small cap | +35.43% |
| ZVRA | Zevra Therapeutics, Inc. | $697.17M | Small cap | +25.43% |
| AQST | Aquestive Therapeutics, Inc. | $676.51M | Small cap | +40.00% |
| CRMD | CorMedix Inc. | $653.95M | Small cap | −40.66% |
| VALN | Valneva SE | $634.84M | Small cap | −23.49% |
| ZURA | Zura Bio Limited | $574.02M | Small cap | +177.31% |
| SPRY | ARS Pharmaceuticals, Inc. | $568.84M | Small cap | −55.13% |
| EPRX | Eupraxia Pharmaceuticals Inc. | $490.26M | Small cap | +40.72% |
| EPRX.TO | Eupraxia Pharmaceuticals Inc. | $487.17M | Small cap | +43.78% |
| RZLT | Rezolute, Inc. | $485.31M | Small cap | −30.00% |
| KMDA | Kamada Ltd. Ordinary Shares | $483.48M | Small cap | +21.09% |
| QTTB | Q32 Bio Inc. | $481.67M | Small cap | +840.70% |
| AVIR | Atea Pharmaceuticals, Inc. | $441.93M | Small cap | +53.06% |
| LRMR | Larimar Therapeutics, Inc. | $432.15M | Small cap | +6.92% |
| XFOR | X4 Pharmaceuticals, Inc. | $412.45M | Small cap | −1.42% |
| ENTA | Enanta Pharmaceuticals, Inc. | $412.12M | Small cap | +65.89% |
| UPB | Upstream Bio, Inc. | $390.52M | Small cap | −57.31% |
| IFRX | InflaRx N.V. | $356.63M | Small cap | +142.00% |
| IKT | Inhibikase Therapeutics, Inc. | $347.44M | Small cap | +39.11% |
| PRQR | ProQR Therapeutics N.V. | $331.63M | Small cap | +6.33% |
| TRDA | Entrada Therapeutics, Inc. | $296.70M | Small cap | +23.24% |
| FULC | Fulcrum Therapeutics, Inc. | $294.51M | Small cap | −41.78% |
| TTRX | Turn Therapeutics Inc. | $292.44M | Small cap | +37.57% |
| SION | Sionna Therapeutics, Inc. | $282.58M | Small cap | −75.45% |
| ELDN | Eledon Pharmaceuticals, Inc. | $272.22M | Small cap | +29.84% |
| IVVD | Invivyd, Inc. | $265.78M | Small cap | +3.52% |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $263.56M | Small cap | +178.15% |
| SLGL | Sol-Gel Technologies Ltd. | $260.05M | Small cap | +261.87% |
| AKBA | Akebia Therapeutics, Inc. | $251.20M | Small cap | −69.88% |
| CRDL | Cardiol Therapeutics Inc. | $250.00M | Small cap | +91.07% |
| CRDL.TO | Cardiol Therapeutics Inc. | $249.99M | Small cap | +90.38% |
| PEPG | PepGen Inc. | $237.21M | Small cap | +159.68% |
| RNA | Prosensa Holding B.V. Ordinary Shares | $236.91M | Small cap | −6.10% |
| SIGA | SIGA Technologies, Inc. | $220.58M | Small cap | −57.93% |
| KROS | Keros Therapeutics, Inc. | $220.48M | Small cap | −28.35% |
| ANTX | AN2 Therapeutics, Inc. | $208.68M | Small cap | +385.09% |
| ARMP | Armata Pharmaceuticals, Inc. | $202.64M | Small cap | +123.36% |
| MSCL.TO | Satellos Bioscience Inc. | $199.95M | Small cap | +81.67% |
| PLX | Protalix BioTherapeutics, Inc. | $199.82M | Small cap | +55.00% |
| MSLE | Satellos Bioscience Inc. | $198.59M | Small cap | +77.27% |
| SPRB | Spruce Biosciences, Inc. | $176.69M | Small cap | +721.93% |
| MDWD | MediWound Ltd. | $163.96M | Small cap | −25.29% |
| EQ | Equillium, Inc. | $149.64M | Small cap | +23.56% |
| AARD | Aardvark Therapeutics, Inc. | $149.04M | Small cap | −24.25% |
| UNCY | Unicycive Therapeutics, Inc. | $148.74M | Small cap | +27.17% |
| MIST | Milestone Pharmaceuticals Inc. | $146.91M | Small cap | −33.33% |
| INO | Inovio Pharmaceuticals, Inc. | $134.42M | Small cap | −47.15% |
| CPIX | Cumberland Pharmaceuticals Inc. | $130.35M | Small cap | +163.82% |
| RFL | Rafael Holdings, Inc. | $119.08M | Small cap | +52.67% |
| MDP.TO | Medexus Pharmaceuticals Inc. | $117.29M | Small cap | +66.56% |
| PYPD | PolyPid Ltd. | $103.79M | Small cap | +49.42% |
| PTHS | Pelthos Therapeutics Inc. | $102.53M | Small cap | +12.90% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.